Literature DB >> 16690728

Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

R H Scott1, C A Stiller, L Walker, N Rahman.   

Abstract

Wilms tumour has been reported in association with over 50 different clinical conditions and several abnormal constitutional karyotypes. Conclusive evidence of an increased risk of Wilms tumour exists for only a minority of these conditions, including WT1 associated syndromes, familial Wilms tumour, and certain overgrowth conditions such as Beckwith-Wiedemann syndrome. In many reported conditions the rare co-occurrence of Wilms tumour is probably due to chance. However, for several conditions the available evidence cannot either confirm or exclude an increased risk, usually because of the rarity of the syndrome. In addition, emerging evidence suggests that an increased risk of Wilms tumour occurs only in a subset of individuals for some syndromes. The complex clinical and molecular heterogeneity of disorders associated with Wilms tumour, together with the apparent absence of functional links between most of the known predisposition genes, suggests that abrogation of a variety of pathways can promote Wilms tumorigenesis.

Entities:  

Mesh:

Year:  2006        PMID: 16690728      PMCID: PMC2564568          DOI: 10.1136/jmg.2006.041723

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  210 in total

1.  Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism.

Authors:  K Avela; M Lipsanen-Nyman; N Idänheimo; E Seemanová; S Rosengren; T P Mäkelä; J Perheentupa; A D Chapelle; A E Lehesjoki
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

2.  Pierre Robin syndrome and Wilms tumor: an unusual association.

Authors:  F D Camassei; A Jenkner; E Bertini; C Bosman; A Donfrancesco; R Boldrini
Journal:  Med Pediatr Oncol       Date:  2000-07

3.  Chromosomal instability syndrome of total premature chromatid separation with mosaic variegated aneuploidy is defective in mitotic-spindle checkpoint.

Authors:  S Matsuura; E Ito; H Tauchi; K Komatsu; T Ikeuchi; T Kajii
Journal:  Am J Hum Genet       Date:  2000-06-30       Impact factor: 11.025

4.  Wilms tumor in a child with trisomy 13.

Authors:  H Sweeney; J Pelegano
Journal:  J Pediatr Hematol Oncol       Date:  2000 Mar-Apr       Impact factor: 1.289

5.  Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group.

Authors:  M H Porteus; P Narkool; D Neuberg; K Guthrie; N Breslow; D M Green; L Diller
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

6.  The occurrence of Wilms tumor in horseshoe kidneys: a report from the National Wilms Tumor Study Group (NWTSG).

Authors:  Holly Neville; Michael L Ritchey; Robert C Shamberger; Gerald Haase; Sharon Perlman; Teri Yoshioka
Journal:  J Pediatr Surg       Date:  2002-08       Impact factor: 2.545

7.  Renal abnormalities in beckwith-wiedemann syndrome are associated with 11p15.5 uniparental disomy.

Authors:  Michael Goldman; Adam Smith; Cheryl Shuman; Oana Caluseriu; Chihong Wei; Leslie Steele; Peter Ray; Paul Sadowski; Jeremy Squire; Rosanna Weksberg; Norman D Rosenblum
Journal:  J Am Soc Nephrol       Date:  2002-08       Impact factor: 10.121

8.  Bilateral nephroblastoma in familial Hay-Wells syndrome associated with familial reticulate pigmentation of the skin.

Authors:  Ricardo Drut; Daniel Pollono; Rosa Mónica Drut
Journal:  Am J Med Genet       Date:  2002-06-15

Review 9.  Controversies and advances in the management of Wilms' tumour.

Authors:  K Pritchard-Jones
Journal:  Arch Dis Child       Date:  2002-09       Impact factor: 3.791

10.  P53 germline mutations in childhood cancers and cancer risk for carrier individuals.

Authors:  A Chompret; L Brugières; M Ronsin; M Gardes; F Dessarps-Freichey; A Abel; D Hua; L Ligot; M G Dondon; B Bressac-de Paillerets; T Frébourg; J Lemerle; C Bonaïti-Pellié; J Feunteun
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

View more
  67 in total

Review 1.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Authors:  Richard D Williams; Reem Al-Saadi; Tasnim Chagtai; Sergey Popov; Boo Messahel; Neil Sebire; Manfred Gessler; Jenny Wegert; Norbert Graf; Ivo Leuschner; Mike Hubank; Chris Jones; Gordan Vujanic; Kathy Pritchard-Jones
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

3.  Risk factors for end stage renal disease in non-WT1-syndromic Wilms tumor.

Authors:  Jane Lange; Susan M Peterson; Janice R Takashima; Yevgeny Grigoriev; Michael L Ritchey; Robert C Shamberger; J Bruce Beckwith; Elizabeth Perlman; Daniel M Green; Norman E Breslow
Journal:  J Urol       Date:  2011-06-17       Impact factor: 7.450

4.  Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.

Authors:  Gulisa Turashvili; Daniel J Fix; Robert A Soslow; Kay J Park
Journal:  Int J Gynecol Pathol       Date:  2018-12-03       Impact factor: 2.762

5.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

6.  Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.

Authors:  Steven Klein; Hane Lee; Shahnaz Ghahremani; Pamela Kempert; Mariam Ischander; Michael A Teitell; Stanley F Nelson; Julian A Martinez-Agosto
Journal:  J Med Genet       Date:  2014-03-27       Impact factor: 6.318

7.  Chromosome-wide gene dosage rebalance may benefit tumor progression.

Authors:  Honglei Zhang; Xing Yang; Xu Feng; Haibo Xu; Qin Yang; Li Zou; Mei Yan; Dequan Liu; Xiaosan Su; Baowei Jiao
Journal:  Mol Genet Genomics       Date:  2018-03-15       Impact factor: 3.291

Review 8.  Nephroblastomatosis or Wilms tumor in a fourth patient with a somatic PIK3CA mutation.

Authors:  Karen W Gripp; Laura Baker; Vinay Kandula; Katrina Conard; Mena Scavina; Joseph A Napoli; Gregory C Griffin; Mihir Thacker; Rachel G Knox; Graeme R Clark; Victoria E R Parker; Robert Semple; Ghayda Mirzaa; Kim M Keppler-Noreuil
Journal:  Am J Med Genet A       Date:  2016-05-18       Impact factor: 2.802

9.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

10.  A new familial cancer syndrome including predisposition to Wilms tumor and neuroblastoma.

Authors:  Fatemeh Abbaszadeh; Karen T Barker; Carmel McConville; Richard H Scott; Nazneen Rahman
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.